Among the study's aims is determining how rates of SARS-CoV-2 infection differ between healthy children and ones with asthma or other allergic conditions.
The aim will be to establish the performance of serology tests for COVID-19 that are being marketed without FDA review and those seeking Emergency Use Authorization.
Policymakers have touted such tests as key to easing shutdowns, but high specificity will be needed to avoid misinforming people about their infection status.
Healthy adults from across the US with no confirmed history of COVID-19 and no current symptoms are eligible to participate and will be enrolled over the phone.
Its most advanced gene expression signatures are for infectious disease diagnostics and are aimed at enabling the appropriate prescription of antiviral and antibiotic medications.
